<DOC>
	<DOCNO>NCT02733094</DOCNO>
	<brief_summary>The purpose study explore efficacy safety anti-Interleukin- ( IL ) 17 therapy ( secukinumab , administer weekly 4 week follow four-weekly administration week 16 ) treatment pyoderma gangrenosum .</brief_summary>
	<brief_title>Single-arm Study Assess Potential Effect Anti-IL-17 ( Secukinumab ) Treatment Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Confirmed diagnosis Pyoderma gangrenosum Biopsyproven , nonhealing ulcer primarily neutrophil infiltration , regardless size location Characterization target lesion ( size , PGA , duration ) 1875 year age Body weight ≥ 40 kg ≤ 160 kg Signed informed consent Key Permanent severe disease , especially affect immune system Pregnancy breast feed History presence epilepsy , significant neurological disorder , cerebrovascular attack ischemia Myocardial infarction cardiac arrhythmia require drug therapy Evidence severe renal dysfunction significant hepatic disease History irritable bowel disease History lymphoproliferative disorder Evidence active infection include limited active tuberculosis , HIV hepatitis B/C opinion investigator would compromise patient 's ability tolerate therapy History malignancy organ system , treat untreated , whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>